New large-capacity bioprocessing centrifuge enhances productivity and reliability
Thermo Scientific Sorvall BIOS 16 centrifuge is designed to provide simplified, flexible bioprocessing.
Thermo Scientific Sorvall BIOS 16 centrifuge designed to provide simplified, flexible bioprocessing.
Designed to maximize productivity for bioprocessing customers, the new Thermo Scientific Sorvall BIOS 16 centrifuge offers an increased capacity of up to 16 liters of cell culture product per run and unique design features to make working with large volumes easier and more convenient.
In the increasingly complex, regulated and fast-paced bioprocessing environment, users require a centrifuge with simple operation and high-throughput capabilities that deliver run-to-run reproducibility while maintaining sample integrity. These elements are essential to manufacturing products in a scalable, consistent and safe manner. In the development and manufacturing of biological products, centrifuges that support separation and purification processes are typically larger and are used continuously. Therefore, users put a high priority on ergonomically designed platforms.
The Thermo Scientific Sorvall BIOS 16 centrifuge includes several features designed to enhance the user experience, including
“For more than 60 years, Thermo Fisher Scientific has demonstrated application expertise across its centrifuge systems, and the addition of the Sorvall BIOS 16 bioprocessing centrifuge builds upon that commitment to delivering innovative designs to meet specific user needs,” said Monica Manotas, vice president and general manager, growth, protection and separation products at Thermo Fisher Scientific. “Now, bioprocessing centers around the world can reap the benefits of this unique, user-friendly system designed to provide high-throughput sample processing, simple, quick set-up and remote monitoring, energy savings, compliance with global safety standards and enhanced ergonomics with every run.”
The new Sorvall BIOS 16 bioprocessing centrifuge offers the flexibility to select higher-capacity rotors or match existing workflows, with a choice of four swinging bucket rotors ranging from 6 x 1000 mL to 8 x 2000 mL. This product is listed with the FDA and complies with the latest global safety standards including UL and CE.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...